A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.

more

Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.

Sign up for our monthly newsletter and review of recent literature!

ribs_resized

First patient enrolled in STREAM Stage II,

the first Phase III clinical study to test bedaquiline

in a shortened treatment regimen for MDR-TB

 

In April 2016 the International Union Against Tuberculosis and Lung Disease and its affiliate Vital Strategies, announced that the STREAM Stage 2 clinical study has begun enrolling patients in Mongolia. This is the first phase III clinical trial to test the effectiveness of bedaquiline within a shortened MDR-TB treatment regimen. The STREAM Stage 2 study protocol includes an all-oral 9-month regimen and a 6- month regimen, both of which include bedaquiline. Read the full press release from the Union here.

 

Recent News and Announcements

Webinar | endTB Clinical Trial: Evaluating Newly approved Drugs for Multidrug-Resistant TB | Thursday, June 9th from 9-10 EDT (15-16 CET)

Join us on Thursday, June 9th from 9-10 EDT (15-16 CEST) for a webinar entitled “endTB Clinical Trial: Evaluating Newly approved Drugs for Multidrug-Resistant TB.” This webinar will provide an update on the design, study start-up, study sites, and anticipated timeline of the endTB clinical trial, a Phase III trial, using Bayesian outcome-adapted randomization to examine […]

UN Zero Draft Political Declaration calls for Joint Action on TB and AIDS

This April the co-facilitators leading negotiations for the 2016 United Nations High-Level Meeting on Ending AIDS, the UN Permanent Representatives of Switzerland and Zambia, released the Zero Draft Political Declaration. The Zero Draft contains commitments which aim to end AIDS and TB epidemics by 2030, and will be negotiated and finalized by governments leading up to […]

First patient enrolled in STREAM Stage II, the first Phase III clinical study to test bedaquiline in a shortened treatment regimen for MDR-TB

In April 2016 the International Union Against Tuberculosis and Lung Disease and its affiliate Vital Strategies, announced that the STREAM Stage 2 clinical study has begun enrolling patients in Mongolia. This is the first phase III clinical trial to test the effectiveness of bedaquiline within a shortened MDR-TB treatment regimen. The STREAM Stage 2 study protocol […]

World TB Day 2016 

During the month of March, Stop TB partnership works to push the issue of TB higher on the agendas of decision makers, stakeholders, governments, programs, partners and communities. This year Stop TB Partnership aims to make not only March 24th, but the whole month of March especially impactful. To learn more about World TB day and […]

Phase 1 Clinical Trial of TB Drug Candidate TBA-354 Discontinued

In March 2016 TB Alliance has announced that it has stopped the clinical development program for the tuberculosis (TB) drug candidate TBA-354. This follows the voluntary hold it placed on the Multiple Ascending Dose (MAD) Phase 1 study of TBA-354 in January 2016. To read the full article visit the TB Alliance website here 

Event Calendar

Social Media